Polio eradication

The Executive Board, having considered the report on poliomyelitis: polio eradication, noting with great concern the evolving public health emergency associated with the increase in new emergences due to circulating vaccine-derived poliovirus type 2, particularly in parts of Africa; and noting the development of the draft Strategy for Control of cVDPV2 2019–2021, an addendum to the Polio Endgame Strategy 2019–2023, to more effectively address the evolving circulating vaccine-derived poliovirus type 2 epidemiology, decided:

(1) to request the Director-General to: (a) continue to ensure adequate and uninterrupted supply of oral polio vaccine type 2 to respond to such outbreaks, in line with existing mandates; (b) accelerate the assessment and roll-out of a novel oral polio vaccine type 2 including through the WHO Emergency Use Listing procedure; (c) initiate a transparent and evidence-based process for prioritizing the equitable allocation of limited supplies of novel oral polio vaccine type 2; and

(2) to urge Member States to: (a) implement an expedited process for national approval of the importation and use of vaccines to respond to polio outbreaks, including novel oral polio vaccine type 2 on the basis of its emergency use listing which includes careful and rigorous analysis of available quality, safety and efficacy data; and (b) mobilize domestic financial resources to complement international financial and political commitments.

Eleventh meeting, 7 February 2020
EB146/SR/11

---

1 Document EB146/21.